CanSino's Supplemental Application for Meningococcal Vaccine Accepted in China

MT Newswires Live

2024/11/27

China's National Medical Products Administration accepted CanSino Biologics' (HKG:6185, SHA:688185) supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.

Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.

Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2486987058"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486987058\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486987058?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486987058","market":"us","top_or_hot":-1,"title":"CanSino's Supplemental Application for Meningococcal Vaccine Accepted in China","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration accepted CanSino Biologics' (HKG:6185, SHA:688185) supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.</p><p>Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.</p><p>Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino's Supplemental Application for Meningococcal Vaccine Accepted in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino's Supplemental Application for Meningococcal Vaccine Accepted in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-11-27 12:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration accepted CanSino Biologics' (HKG:6185, SHA:688185) supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.</p><p>Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.</p><p>Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"醫藥製造","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486987058","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486987058","pubTimestamp":1732680117,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration accepted CanSino Biologics'  supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688185":"康希诺","BK0239":"医药制造","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","06185":"康希诺生物"},"translate_title":"康希诺脑膜炎球菌疫苗补充申请在中国获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06185":0.9},"content_text":"China's National Medical Products Administration accepted CanSino Biologics' (HKG:6185, SHA:688185) supplemental application for Menhycia, its ACYW135 meningococcal polysaccharide conjugate vaccine.Through the application, the drugmaker seeks to expand the vaccine's applicable age range to children aged 3 months to 6 years old from the earlier approved range of 3 months to 3 years old, according to a Tuesday filing with the Hong Kong Exchange.Cansino's Menhycia is the first MCV4 vaccine product in China, the filing stated.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}